Khalid Mahmood
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Khalid Mahmood has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Abdullah K. Alanazi
Department of Chemistry, College of Science, Taif University, Taif, Saudi Arabia
1 shared publicationDure Shahwar
Department of Pharmaceutics, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan
1 shared publication- Farhan Siddique
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan
1 shared publication Halil Şenol
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Bezmialem Vakif University, Fatih, Turkey
1 shared publicationHuma Butt
Department of Pharmaceutics, Faculty of Pharmacy, The Islamia University of Bahawalpur, Punjab, Pakistan
1 shared publicationKhawar Abbas
Institute of Chemical Sciences, Bahauddin Zakariya University, Multan, Pakistan
1 shared publication
Latest Publications
- Open Access
- 25 November 2025
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 40 (1) , 1
Design, synthesis, pharmacological evaluation and computational modeling of 4-formyl-2-nitrophenyl quinoline-8-sulfonate derived thiosemicarbazones as antidiabetic agents
A novel series of thiosemicarbazone derivatives 6(a–i), synthesized from 4-formyl-2-nitrophenyl quinoline-8-sulfonate, was evaluated for its antidiabetic potential. Among them, compound 6i (IC₅₀ = 54.51 ± 0.84 µM) displayed the most potent α-glucosidase inhibition, whereas 6e (IC₅₀ = 9.66 ± 0.14 µM) exhibited superior α-amylase inhibition, indicating their dual therapeutic potential against key carbohydrate-hydrolyzing enzymes implicated in postprandial hyperglycemia. These derivatives showed structural diversity with potent and selective inhibition profiles. Structure-activity relationship analysis revealed that electron-withdrawing substituents enhanced enzyme affinity and biological activity. However, molecular docking studies demonstrated strong binding affinities for compounds 6f and 6b with docking scores of − 9.1 to − 10.4 kcal/mol against target proteins, via hydrogen bonding and π–π interactions with catalytic residues. Furthermore, in-silico ADMET evaluation predicted good oral bioavailability, low toxicity, and favorable pharmacokinetic properties. The Density Functional Theory (DFT) calculations supported experimental results, where studied compounds showed lower HOMO-LUMO energy gaps (2.41–3.42 eV), suggesting their significant chemical reactivity and molecular stability of these compounds. Overall, in-vitro and in-silico studies revealed that compounds 6b, 6f, 6e, and 6i emerged as promising lead molecules for developing dual-action therapeutic agents targeting hyperglycemia and oxidative damage in diabetes management.
- 25 November 2025
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 40 (1) , 1
Open AccessDesign, synthesis, pharmacological evaluation and computational modeling of 4-formyl-2-nitrophenyl quinoline-8-sulfonate derived thiosemicarbazones as antidiabetic agents
A novel series of thiosemicarbazone derivatives 6(a–i), synthesized from 4-formyl-2-nitrophenyl quinoline-8-sulfonate, was evaluated for its antidiabetic potential. Among them, compound 6i (IC₅₀ = 54.51 ± 0.84 µM) displayed the most potent α-glucosidase inhibition, whereas 6e (IC₅₀ = 9.66 ± 0.14 µM) exhibited superior α-amylase inhibition, indicating their dual therapeutic potential against key carbohydrate-hydrolyzing enzymes implicated in postprandial hyperglycemia. These derivatives showed structural diversity with potent and selective inhibition profiles. Structure-activity relationship analysis revealed that electron-withdrawing substituents enhanced enzyme affinity and biological activity. However, molecular docking studies demonstrated strong binding affinities for compounds 6f and 6b with docking scores of − 9.1 to − 10.4 kcal/mol against target proteins, via hydrogen bonding and π–π interactions with catalytic residues. Furthermore, in-silico ADMET evaluation predicted good oral bioavailability, low toxicity, and favorable pharmacokinetic properties. The Density Functional Theory (DFT) calculations supported experimental results, where studied compounds showed lower HOMO-LUMO energy gaps (2.41–3.42 eV), suggesting their significant chemical reactivity and molecular stability of these compounds. Overall, in-vitro and in-silico studies revealed that compounds 6b, 6f, 6e, and 6i emerged as promising lead molecules for developing dual-action therapeutic agents targeting hyperglycemia and oxidative damage in diabetes management.
- 22 May 2025
- Published by Springer Nature in BioMetals
- Vol. 38 (4) , 1027-1048
Therapeutic applications of quercetin-metallic complexes: a review
Flavonoids, especially quercetin, are widely recognized for their antioxidant, anti-inflammatory, anti-microbial, anti-diabetic, and anti-tumor properties, but their clinical application is limited by poor permeability. Different techniques of permeability enhancement of quercetin, i.e., preparation of phytosomes, conjugation with glucose, and interaction of piperine, are reported extensively, but formation of metal complexes is considered more precise and reliable. This review focuses on research conducted on the chelation of quercetin with metals, i.e., copper (II), zinc (II), iron and ruthenium. In-vitro and in-vivo therapeutic activities, biomedical applications of metal/quercetin inclusion complexes and discussions of stability concerns of quercetin alone and its metallic complexes. Conjugation of metals with quercetin augments its potential to the next level. Numerous studies revealed that quercetin/copper (Q/Cu) and quercetin/zinc (Q/Zn) can become efficacious candidates in acute myeloid leukaemia, orthopaedics and severe acute respiratory syndrome coronavirus (SARS-CoV) infection. Graphical abstract Graphical representation of Q/Zn and Q/Cu complexes and their biomedical applications.
- 22 May 2025
- Published by Springer Nature in BioMetals
- Vol. 38 (4) , 1027-1048
Therapeutic applications of quercetin-metallic complexes: a review
Flavonoids, especially quercetin, are widely recognized for their antioxidant, anti-inflammatory, anti-microbial, anti-diabetic, and anti-tumor properties, but their clinical application is limited by poor permeability. Different techniques of permeability enhancement of quercetin, i.e., preparation of phytosomes, conjugation with glucose, and interaction of piperine, are reported extensively, but formation of metal complexes is considered more precise and reliable. This review focuses on research conducted on the chelation of quercetin with metals, i.e., copper (II), zinc (II), iron and ruthenium. In-vitro and in-vivo therapeutic activities, biomedical applications of metal/quercetin inclusion complexes and discussions of stability concerns of quercetin alone and its metallic complexes. Conjugation of metals with quercetin augments its potential to the next level. Numerous studies revealed that quercetin/copper (Q/Cu) and quercetin/zinc (Q/Zn) can become efficacious candidates in acute myeloid leukaemia, orthopaedics and severe acute respiratory syndrome coronavirus (SARS-CoV) infection. Graphical abstract Graphical representation of Q/Zn and Q/Cu complexes and their biomedical applications.